Strategies for unlocking immunosuppression in the tumor microenvironment have been
investigated to overcome resistance to first-generation immune checkpoint blockade with …

Metabolic reprogramming in cancer is not only a biological hallmark but also reveals
treatment vulnerabilities. Numerous metabolic molecules have shown promise as treatment …

Aryl hydrocarbon receptor (AHR) activation by tryptophan (Trp) catabolites enhances tumor
malignancy and suppresses anti-tumor immunity. The context specificity of AHR target …

Tumor immunometabolism contributes substantially to tumor proliferation and immune cell
activity, and thus plays a crucial role in the efficacy of cancer immunotherapy. Modulation of …

The advent of immune checkpoint inhibition (ICI) using antibodies against PD1 and its
ligand PDL1 has prompted substantial efforts to develop complementary drugs. Although …

Diseases of the central nervous system (CNS) remain a significant health, social and
economic problem around the globe. The development of therapeutic strategies for CNS …

Metabolic reprogramming of the tumor microenvironment (TME) and poor immunogenicity
are two of the challenges that cancer immunotherapies have to overcome for improved …

The activities of non-haematopoietic cells (NHCs), including mesenchymal stromal cells and
endothelial cells, in lymphomas are reported to underlie lymphomagenesis. However, our …

Amino acids are fundamental units of molecular components that are essential for sustaining
life; however, their metabolism is closely interconnected to the control systems of cell …

Abstract Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade
has been approved as the standard-of-care for the treatment of non-small cell lung cancer …